Leah Rush Cann

The development-stage biotechnology company Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) uses protein interaction to treat myelofibrosis, in addition to addressing prostate cancer and other tumors. The Analysts Oppenheimer analyst Leah Rush Cann initiated coverage of ...

Miragen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotech company, has product candidates for hematologic cancers and fibrotic diseases in its pipeline. The Analyst Oppenheimer analyst Leah Rush Cann initiated coverage of Miragen with an Outperform and a 12-18-month price...

Syros Pharmaceuticals Inc (NASDAQ: SYRS) reported initial clinical data over the weekend from an ongoing Phase 2 study of its SY-1425 and SY-1365 therapies for the treatment of genetically defined acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS.  The Analyst...

Oppenheimer has upgraded Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares to Outperform from Perform on higher expectations for its first drug launch and attractive valuation. The company’s AG-221, developed along with partner Celgene Corporation (NASDAQ: CELG), is submitted for FDA approval...

Oppenheimer said Amgen, Inc. (NASDAQ: AMGN) is at an inflection point, driven by growth from replacement products and uniquely positioned to benefit from the emerging field of biosimilars. Analyst Leah Rush Cann has launched coverage of Amgen with an Outperform rating and price target of $166. Rush...